Showing results (171-180 of 183) with videos related to
Sort By:
Pageof 19
Psychiatry Research|December 9, 2017
Predictors of remission from PTSD symptoms after sexual and non-sexual trauma in the community: A mediated survival-analytic approachMario Müller, Vladeta Ajdacic-Gross, Stephanie Rodgers, et al.Frontiers in Psychiatry|August 7, 2018
Psychiatric In-Patients Are More Likely to Meet Recommended Levels of Health-Enhancing Physical Activity If They Engage in Exercise and Sport Therapy ProgramsJanine Ehrbar, Serge Brand, Flora Colledge, et al.Psychiatry Research|June 16, 2022
Utility and validity of the Brief Psychiatric Rating Scale (BPRS) as a transdiagnostic scaleAndreas B Hofmann, Hanna M Schmid, Mounira Jabat, et al.Journal of the American Chemical Society|June 2, 2022
Localized Antiaromaticity Hotspot Drives Reductive Dehydrogenative Cyclizations in Bis- and Mono-HelicenesZheng Zhou, Dominic T Egger, Chaowei Hu, et al.British Journal of Cancer|April 1, 2004
Capecitabine in hormone-resistant metastatic prostatic carcinoma - a phase II trialR Morant, J Bernhard, D Dietrich, et al.Science Immunology|July 21, 2023
NLRP11 is a pattern recognition receptor for bacterial lipopolysaccharide in the cytosol of human macrophagesMaricarmen Rojas-Lopez, María Luisa Gil-Marqués, Vritti Kharbanda, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 21, 2005
Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK)M Ghielmini, K Rufibach, G Salles, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 8, 2006
Concerted escalation of dose and dosing duration in a phase I study of the oral camptothecin gimatecan (ST1481) in patients with advanced solid tumorsC Sessa, S Cresta, T Cerny, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 16, 2002
Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine) by subcutaneous bolus injection: a phase II studyA von Rohr, S-F H Schmitz, A Tichelli, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 5, 2006
Sequential high dose chemotherapy as initial treatment for aggressive sub-types of non-Hodgkin lymphoma: results of the international randomized phase III trial (MISTRAL)D C Betticher, G Martinelli, J A Radford, et al.Pageof 19